BLTE vs. RVMD, ELAN, LEGN, GRFS, TLX, TGTX, LNTH, NUVL, AXSM, and AKRO
Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.
Belite Bio vs. Its Competitors
Revolution Medicines (NASDAQ:RVMD) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.
Revolution Medicines has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, suggesting that its stock price is 250% less volatile than the S&P 500.
Revolution Medicines currently has a consensus price target of $67.58, suggesting a potential upside of 83.20%. Belite Bio has a consensus price target of $96.67, suggesting a potential upside of 69.12%. Given Revolution Medicines' higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Belite Bio.
Belite Bio's return on equity of -32.07% beat Revolution Medicines' return on equity.
Belite Bio has lower revenue, but higher earnings than Revolution Medicines. Belite Bio is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.
In the previous week, Revolution Medicines had 11 more articles in the media than Belite Bio. MarketBeat recorded 14 mentions for Revolution Medicines and 3 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.66 beat Revolution Medicines' score of 0.60 indicating that Belite Bio is being referred to more favorably in the news media.
94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 8.2% of Revolution Medicines shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Revolution Medicines beats Belite Bio on 7 of the 13 factors compared between the two stocks.
Get Belite Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belite Bio Competitors List
Related Companies and Tools
This page (NASDAQ:BLTE) was last updated on 7/2/2025 by MarketBeat.com Staff
